ArticleAdvanced healthcare materials2025
Light-Activatable Hyaluronic Acid-Derivatives Releasing Nitric Oxide and Their Delivery in the Skin.
Article in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Vincristine Beyond Mitosis: Uncovering a First Link to G-Quadruplex DNA in Cancer Cells.International journal of molecular sciences · 2025Article
- Light-Activatable Hyaluronic Acid-Derivatives Releasing Nitric Oxide and Their Delivery in the Skin.Advanced healthcare materials · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Hyaluronic acid (HA), renowned for its hydrating properties, penetrates deeper into the skin at a very low molecular weight, promoting cellular repair and reducing inflammation. Nitric oxide (NO), a gaseous mediator with a very relevant role in many physiological and pathophysiological processes, is expected to complement the functions of HA in the skin through its vasodilatory, anti-inflammatory, and regenerative properties. Herein, a novel class of HA derivatives functionalized with NO photodonors (NOPD) for light-activated therapeutic applications is introduced. The HA derivatives HA-NOPD1 and HA-NOPD2 demonstrated NO release under blue light activation. Biological assays on HaCaT keratinocytes revealed enhanced proliferation and migration under light stimuli, underscoring the therapeutic potential of HA-NOPD1. The derivatives are formulated into microemulsions (MEs) to allow their skin transport. MEs loaded with the photoresponsive derivatives are stable in the dark and provide effective NO photorelease with higher quantum yields than the free compounds. Skin permeation studies using porcine and artificial membranes confirmed that HA-NOPD2 distributed in all the skin layers, reaching the dermis and releasing NO in situ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.